Evidence map›Paper›PMID 37984194›Full record

ArticleAtherosclerosis2023

Performance of the enhanced Sampson-NIH equation for VLDL-C and LDL-C in a population with familial combined hyperlipidemia.

Rafael Zubirán, Arsenio Vargas-Vazquez, Fabiola Del Razo Olvera, Ivette Cruz-Bautista, Alexandro Martagón-Rosado, Maureen Sampson, Alan T Remaley, Carlos A Aguilar-Salinas

Open access · greenAbstract read
In one paragraph

Article in Atherosclerosis, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Interaction Between Primary Hyperlipidemias and Type 2 Diabetes: Therapeutic Implications.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2024
    Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 3 countries.

Rafael ZubiránMetabolic Diseases Research Department, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, 14080 Mexico City, Mexico; Lipoprotein Metabolism Laboratory, Translational Vascular Medicine Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Arsenio Vargas-VazquezMetabolic Diseases Research Department, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, 14080 Mexico City, Mexico; Department of Medical Education, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, 14080 Mexico City, Mexico.
Fabiola Del Razo OlveraMetabolic Diseases Research Department, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, 14080 Mexico City, Mexico.
Ivette Cruz-BautistaMetabolic Diseases Research Department, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, 14080 Mexico City, Mexico.
Alexandro Martagón-RosadoMetabolic Diseases Research Department, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, 14080 Mexico City, Mexico; Escuela de Medicina y Ciencias de la Salud, Tecnologico de Monterrey, Mexico City 64700, Mexico; Institute for Obesity Research, Tecnologico de Monterrey, Mexico City 64700, Mexico.
Maureen SampsonDepartment of Laboratory Medicine, Clinical Center, National Institutes of Health, Bethesda, MD 20892, USA.
Alan T RemaleyLipoprotein Metabolism Laboratory, Translational Vascular Medicine Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Carlos A Aguilar-SalinasMetabolic Diseases Research Department, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, 14080 Mexico City, Mexico; Escuela de Medicina y Ciencias de la Salud, Tecnologico de Monterrey, Mexico City 64700, Mexico; Department of Investigation, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, 14080 Mexico City, Mexico; Gilbert and Rose-Marie Chagoury School of Medicine, Lebanese American University, Beirut, Lebanon. Electronic address: caguilarsalinas@yahoo.com.
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán · MXNational Institutes of Health · USNational Institutes of Health Clinical Center · US

Funding

Intramural NIH HHS Z99 HL999999
6 · The paper itself

Abstract

introductionLow-density cholesterol (LDL-C) has long been estimated by the Friedewald formula (F-LDL-C); however, this method underestimates LDL-C in patients with hypertriglyceridemia (HTG) or low LDL-C levels. The Martin (M-LDL-C) and Sampson (S-LDL-C) formulas partially resolve these limitations. Recently, Sampson et al. developed a new equation (eS-VLDL-C) that includes ApoB. This new equation could be particularly useful in FCHL, which is characterized by the predominance of triglyceride-rich VLDL and a discordance between LDL-C and ApoB.

methodsVery low-density lipoproteins (VLDL-C) was measured in 336 patients with FCHL by sequential ultracentrifugation. LDL-C was estimated by subtracting VLDL-C, estimated by the different equations, from non-HDL cholesterol. Spearman correlations, R

resultsOverall population had a mean age of 47 years, and 61.5% were women. 19.5% had type 2 diabetes, hypertension was present in 20.8%, and only 12.2% were on statin treatment. Both S-LDL-C and eS-LDL-C performed similarly, and better than M-LDL-C and F-LDL-C. In Bland-Altman analysis, eS-LDL-C showed the lowest bias, better performance in HTG, and better concordance with LDL-C treatment goals compared to other formulas (e.g. ρ: 0.87, 95% CI 0.84-0.89).

conclusionsLDL-S and LDL-eS equations estimate the concentration of LDL-C with greater accuracy than other formulas. The LDL-eS has best performance in estimating LDL-C with lower RMSE than other formulas.

Indexed as

Diabetes Mellitus, Type 2Hyperlipidemia, Familial CombinedHyperlipidemiasHypertriglyceridemiaCholesterolCholesterol, LDLFemaleHumansMaleMiddle AgedTriglyceridesCholesterolCholesterol, LDLTriglyceridesCardiovascular riskCholesterolFamilial combined hyperlipidemiaLow-density lipoproteinsTriglycerides

Identifiers

PMID37984194
PMCPMC10841743
OpenAlexW4388419502

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.